CompletedNCT03386851
Aripiprazole Injections in Korean People With Schizophrenia or Bipolarity
About this title
Abilify Maintena PMS in Schizophrenia Patients or Bipolar 1 Disorder
Read the official source —Observational studyAges 19+South Korea
Understand this study
Who was this study for?
Listed age limits: from 19 years.
- Listed locations
- GwangjuSee all locations and recruitment
Study information
Study start dateStarted: December 13, 2016
- Recruitment status
- Completed
- Enrollment listed in the registry
- 1,030
- Sponsor
- Korea Otsuka Pharmaceutical Co., Ltd.
- Sponsor type
- Pharmaceutical company
- Study type
- Observational
- Intervention type
- Interview / survey / observational
- Study phase
- Not clearly listed
- Locations
- South Korea
- Age range
- Over 19 Years
- Official registry ID
- NCT03386851
- Official title
Show the full official title
Post-Marketing Surveillance of Safety and Effectiveness of Abilify Maintena® Injections in Korean Patients With Schizophrenia or Bipolar 1 Disorder Under the "New Drug Re-Examination"
Get this study by email
Recruitment & locations
CompletedGwangju
Questions about this study
Who is behind this study?
The study sponsor is Korea Otsuka Pharmaceutical Co., Ltd., a pharmaceutical company.
Who was this study for?
Listed age limits: from 19 years.
